Nasus Pharma (NSRX) Stock Price

Nasus Pharma Price

CLOSED
3.17
​
Market closed

Nasus Pharma stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nasus Pharma business model & stock analysis

Nasus Pharma Ltd is an Israeli company headquartered in Tel Aviv-Yafo, operating in the pharmaceutical sector. The company is scheduled to go public on August 13, 2025, with the ticker symbol NSRX and ISIN IL0012181553. Nasus Pharma focuses on developing pharmaceutical preparations and intranasal powder-based drug delivery systems. Its technology utilizes microspheres to enable rapid, non-invasive medication administration for conditions including anaphylaxis and opioid overdose. The company's formulations are designed for fast absorption, ease of use, and effectiveness in emergency scenarios. Nasus Pharma's products aim to enhance access to life-saving treatments by facilitating administration by both non-professionals and medical professionals, such as caregivers, emergency nurses, and doctors. The company's website is www.nasuspharma.com. Nasus Pharma does not provide specific details about its founding year, key personnel, or financial figures in the available information. The company's technology is intended for critical medical situations where quick treatment is essential, emphasizing user-friendly delivery methods that do not require specialized medical training for effective use.

Frequently asked questions about Nasus Pharma

8 analysts currently rate the Nasus Pharma stock: 7 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Nasus Pharma share trades at 2.82 EUR (3.17 USD).

The revenue cannot currently be calculated for Nasus Pharma.

The expected profit of Nasus Pharma is -10.18 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Nasus Pharma is currently -2.80. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Nasus Pharma stock.

The P/S cannot be calculated for Nasus Pharma currently.

The Eulerpool Quality Score for Nasus Pharma is 2/10.

The ISIN of Nasus Pharma is IL0012181553. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Nasus Pharma is NSRX. The ticker symbol is used to trade Nasus Pharma shares on the stock exchange.

Fair ValueTerminal
2.95 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Israel
Currency
USD
Initial public offering
Aug 13, 2025
ISIN
IL0012181553
Cusip
M7071P109
Market capitalization
28.53 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-2.80
P/Ee 2027
-2.81
P/Ee 2028
-6.21
P/Ee 2029
11.73
P/Ee 2030
2.28
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
10.31
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-202.91 %
Last updated Oct 16, 2026, 2:33 AM

Nasus Pharma Peer Group